Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Underwriter's have 30 days to purchase remaining over allotments.

I suspect all remaining shares will be purchased at $19.60 by Feb 24. At that point share price will be $25-26, assuming all of the below are included at Q4 earnings call on/about Feb. 8th:

1. Update launch and prescription count for Iclusig.
2. Update enrollment status of EPIC and earlier timeline for 12 mos data (May '14?)
3. Outline additional registration trials and timing for Iclusig in AML, GIST, and NSCLC.
4. Provide MTD and recommended dose for PH2 of '113.
5. Announce timing for IND of 5th molecule (just after ASCO)

With the exception of #5 aren't these overdue?